Literature DB >> 10629441

Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549.

T Yamamoto1, Y Moriwaki, Y Fujimura, S Takahashi, Z Tsutsumi, T Tsutsui, K Higashino, T Hada.   

Abstract

To examine the effect of 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid (TEI-6720), an inhibitor of xanthine oxidase, on purine metabolism in the lung cancer cell line A549, the activities of adenosine deaminase, purine nucleoside phosphorylase, adenine phosphoribosyltransferase, hypoxanthine guanine phosphoribosyltransferase, xanthine oxidase, and guanase together with pyrimidine nucleoside phosphorylase were measured with or without the addition of TEI-6720, and the extracellular concentrations of hypoxanthine, xanthine, inosine, uracil, and uridine were measured after the addition of inosine or uridine to the incubation medium with or without TEI-6720. Moreover, the Na-independent nucleoside transport was determined in A549 cells with or without TEI-6720. TEI-6720 inhibited the activity of xanthine oxidase in A549 cells, but did not affect other enzymes. During incubation, TEI-6720 not only prevented a decrease in the inosine concentration in inosine-containing medium, but also a decrease in the uridine concentration in uridine-containing medium. Furthermore, the Na-independent transport of uridine was inhibited by TEI-6720 with a K(i) value of 4.1 micromol/l. These results indicate that TEI-6720 is an inhibitor of the Na-independent nucleoside transport of uridine and inosine, as well as xanthine oxidase. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629441     DOI: 10.1159/000028344

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  5 in total

1.  Efficacy and safety of febuxostat in patients with hyperuricemia and gout.

Authors:  Ignacio Garcia-Valladares; Tahir Khan; Luis R Espinoza
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-10       Impact factor: 5.346

Review 2.  Febuxostat.

Authors:  Philip I Hair; Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Pharmacology and Clinical Drug Candidates in Redox Medicine.

Authors:  V Thao-Vi Dao; Ana I Casas; Ghassan J Maghzal; Tamara Seredenina; Nina Kaludercic; Natalia Robledinos-Anton; Fabio Di Lisa; Roland Stocker; Pietro Ghezzi; Vincent Jaquet; Antonio Cuadrado; Harald H H W Schmidt
Journal:  Antioxid Redox Signal       Date:  2015-11-06       Impact factor: 8.401

4.  Monosodium Urate and Tumor Necrosis Factor-α Increase Apoptosis in Human Chondrocyte Cultures.

Authors:  Charles J Malemud; Yan Sun; Eric Pearlman; Nell M Ginley; Amad Awadallah; Bradley A Wisler; James E Dennis
Journal:  Rheumatology (Sunnyvale)       Date:  2012-12-26

5.  The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.

Authors:  Tatsuo Hosoya; Kenjiro Kimura; Sadayoshi Itoh; Masaaki Inaba; Shunya Uchida; Yasuhiko Tomino; Hirofumi Makino; Seiichi Matsuo; Tetsuya Yamamoto; Iwao Ohno; Yugo Shibagaki; Satoshi Iimuro; Naohiko Imai; Masanari Kuwabara; Hiroshi Hayakawa
Journal:  Trials       Date:  2014-01-16       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.